Noxopharm

Noxopharm is an Australian-listed (ASX: NOX) clinical-stage drug development company. The clinical-stage candidate drug is Veyonda® (formerly known as NOX-66). Veyonda® is a first-class, dual-action cytotoxic and immuno-oncology candidate drug designed to enhance the efficacy and safety of chemotherapy and radiotherapy. On one hand, Veyonda® enhances the anticancer effects of standard chemotherapy and radiotherapy, allowing for the use of lower doses of these toxic treatments.